JAK2 and acute myeloid leukemia: However, independent studies have shown that compared to CBL wild-type AML cells, CBL mutant AML cells are more sensitive to quizartinib (a FLT3 inhibitor) than ruxolitinib (a JAK2 inhibitor) (Lv et al., 2017).